Strategic Partnerships OmniAb collaborates with pharma and biotech players through partnerships such as VERAXA Biotech integration and bsADC programs, presenting outbound sales opportunities to align OmniAb’s discovery platforms with partner ADC development and bespoke antibody platforms.

Clinical Expansion Active engagement in oncology programs including bispecific antibody-drug conjugates for solid tumors signals a market need for diverse antibody repertoires and targeted discovery capabilities, suggesting cross-sell opportunities into tumor-focused collaborations and translational programs.

Discovery Platform OmniAb offers diverse antibody repertoires and high-throughput screening to pharmaceutical partners, indicating upside in expanding usage across additional therapeutic areas and increasing seat or license uptake through expanded access programs.

Strategic Visibility Frequent participation in investor conferences and industry summits, plus the Partner Access Program for xPloration, creates prequalification and awareness opportunities to engage potential biotech partners seeking advanced discovery tooling and in-house screening capabilities.

Funding & Scale Current revenue range and funding cushion position OmniAb to pursue co-development deals, pilot programs, and scalable collaborations with mid- to large-cap biotechs looking to accelerate discovery timelines using OmniAb’s platforms.